Abstract Library

#4617 Analysis of new immunohistochemical biomarkers in a cohort of pancreatic NETs

Introduction: Pancreatic neuroendocrine tumours (PanNETs) are rare diseases with a 10-year survival rate of only 40-50%. The ATRX, DAXX and ARX, PDX1 expressions in PanNETs were considered poor prognostic factors in some studies, but inconsistent in others.

Conference:

Presenting Author:

Authors: Ciobanu O, Martin S, Herlea V, Vasilescu F, Balaban D,

Keywords: Pancreatic neuroendocrine tumour, ATRX, DAXX, ARX, PDX1,

#4544 Spatial and temporal intratumour heterogeneity of pancreatic neuroendocrine tumours (PanNET)

Introduction: Data derived from the study of intertumour heterogeneity have led to propose that PanNET evolution may start either from beta cells with good prognosis, or from alpha cells with sequential alterations of MDA (MENIN-DAXX/ATRX) leading to more aggressive lesions.

Conference:

Presenting Author: Awan Z

Authors: Awan Z, Bourdeleau P, Epée J, Ps H, Tihy M,

Keywords: Pancreatic neuroendocrine tumour, Heterogeneity, Tumour microenvironment,

#4502 Molecular analysis of non-functioning PanNETs of the alpha lineage reveals new subtypes and mechanisms of progression

Introduction: Most pancreatic neuroendocrine tumours (PanNETs) are non-functioning. Previously, we demonstrated that small, MEN1-only mutated α-like PanNETs can be distinguished from larger ADM (mutated in ATRX, DAXX and MEN1) PanNETs based on epigenetic profiles. ADM PanNETs have shorter disease-free survival and a higher relapse risk. However, their therapeutic responses vary, underscoring group heterogeneity. ADM PanNETs remain insufficiently characterised, with potential subtype-specific progression drivers with implications for treatment choice and clinical outcome.

Conference:

Presenting Author: Avanthay S

Authors: Avanthay S, Di Domenico A, Kirchner P, Bräutigam K, Chouchane A,

Keywords: pancreas, epigenetics, progression, metastasis, DAXX, ATRX, Pan NET,

#4496 ATRX, DAXX, and menin immunohistochemistry identify prognostic relevant non-functioning neuroendocrine tumours subgroups

Introduction: Non-functioning pancreatic neuroendocrine tumours (NF-pNETs) are rare tumours with a variable prognosis. Recent studies have identified prognostic subgroups based on ATRX, DAXX and MEN1 mutations along with chromosomal aneuploidies.

Conference:

Presenting Author: Verschuur A

Authors: Verschuur A, Jairam J, Eldem B, Singhi A, Hackeng W,

Keywords: pancreatic neuroendocrine tumour, ATRX, DAXX, MEN1, menin, biomarker,

#4130 CHGA and DAXX/ATRX expression influence the outcome of pancreatic head neuroendocrine tumors

Introduction: In the past two years a difference between pancreatic neuroendocrine tumors (pNET) located in the head and body/tail regarding biological characteristics and clinical outcomes was described.

Conference:

Presenting Author: Amin T

Authors: Amin T, Viol F, Awwad F, Fründt T, Fraune C,

Keywords: neuroendocrine tumor, pancreatic, DAXX/ATRX, OS,